Fierce Pharma1d
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
BioPharma Dive1d
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...
2NVS : FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...
Swiss drugmakers Novartis and Roche ditch some diversity programmes on US concerns
Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...
Novartis scraps use of diverse panels for hires in US
By Paul Arnold and Maggie Fick ZURICH (Reuters) -Swiss drugmaker Novartis is ending its use of diverse panels for all of its ...
Zacks Investment Research on MSN1d
Here's Why Novartis (NVS) is a Strong Value Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...
Explore more
Fierce Pharma8d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Applied Clinical Trials Online1d
FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto
Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...
STAT10d
Novartis finally delivers gene therapy data in older SMA patients. Will they still want it?
In the time since the Novartis gene therapy Zolgensma was approved for babies with spinal muscular atrophy, other treatments ...
Yahoo Finance9d
Novartis builds case for new SMA gene therapy
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. On Wednesday, Novartis gave a more ...
Healio1d
FDA expands Pluvicto indication for earlier use in patients with prostate cancer
The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...
Novartis9d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...